Breaking News

Purdue Pharma, Medidata Expand Enterprise Agreement

February 25, 2013

Broadens cloud-based solutions for clinical trial operational efficiencies

Purdue Pharma has signed a multi-year enterprise agreement expanding its use of Medidata’s cloud-based solutions aimed at further improving clinical trial operational efficiencies, resource savings and decision making. Purdue is also renewing the Medidata applications it currently uses across its portfolio of treatments for pain, sleep and gastrointestinal disorders, including Medidata Designer and EDC and management system, Medidata Rave.
Purdue has also adopted Medidata’s clinical trial management system (CTMS) and is now adding clinical business analytics with Medidata Insights, including its site quality management module, as well as support for risk-based monitoring with Rave Targeted SDV and additional modules of the site budgeting and financial management tool Medidata Grants Manager.
“After seeing the results we were able to achieve with Medidata’s Clinical Cloud, we have enthusiastically embraced a number of new capabilities,” said Charles Willmer, senior director of clinical systems, Purdue. “Expanding our use of Medidata’s platform will enable us to reduce cost, complexity and time in site negotiation and monitoring, track CRO activities more efficiently, and improve visibility into study performance.”
“As a leader in its industry, Purdue is aggressively developing a holistic and integrated clinical research technology strategy, and with this approach will be better positioned to evolve and strengthen its R&D operations,” said Tarek Sherif, chairman and chief executive officer, Medidata Solutions. “Our cloud-based solution is enabling Purdue to focus on innovation of new therapies while reducing clinical development costs, speeding trials and improving decision making.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research